- In November 2024, Soligenix announced the initiation of a Phase 2 clinical trial (DUS-AUBD-01) for SGX945 (dusquetide) in the treatment of aphthous ulcers in Behçet's Disease. This open-label study aims to enroll approximately 25 patients with mild to moderate BD and active oral and/or genital ulcers, with results anticipated in the first half of 2025
- In October 2022, Pfizer finalized its acquisition of Global Blood Therapeutics (GBT) for USD 5.4 billion, enhancing its portfolio in rare hematology. GBT's expertise in sickle cell disease, including its lead drug Oxbryta, strengthens Pfizer's commitment to addressing underserved patient populations
- In June 2022, Amgen announced the progression of its Phase 3 clinical trials for apremilast in pediatric patients aged 6–17 with active oral ulcers associated with Behçet’s disease. The study is expected to conclude by 2029, potentially offering a new treatment option for this patient group
- In December 2021, Novartis announced the acquisition of Gyroscope Therapeutics, a UK-based company specializing in ocular gene therapy. This acquisition, valued at up to USD 1.5 billion, adds Gyroscope's lead program, GT005, a one-time gene therapy for geographic atrophy, to Novartis' portfolio
